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Abstract: Oceans are a vast source of natural substances. In them, we find various compounds with
wide biotechnological and biomedical applicabilities. The exploitation of the sea as a renewable source
of biocompounds can have a positive impact on the development of new systems and devices for
biomedical applications. Marine polysaccharides are among the most abundant materials in the seas,
which contributes to a decrease of the extraction costs, besides their solubility behavior in aqueous
solvents and extraction media, and their interaction with other biocompounds. Polysaccharides such
as alginate, carrageenan and fucoidan can be extracted from algae, whereas chitosan and hyaluronan
can be obtained from animal sources. Most marine polysaccharides have important biological
properties such as biocompatibility, biodegradability, and anti-inflammatory activity, as well as
adhesive and antimicrobial actions. Moreover, they can be modified in order to allow processing
them into various shapes and sizes and may exhibit response dependence to external stimuli, such as
pH and temperature. Due to these properties, these biomaterials have been studied as raw material for
the construction of carrier devices for drugs, including particles, capsules and hydrogels. The devices
are designed to achieve a controlled release of therapeutic agents in an attempt to fight against serious
diseases, and to be used in advanced therapies, such as gene delivery or regenerative medicine.
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1. Introduction
Marine organisms are a vast source of different compounds with diverse biological properties and
bioactivity. Recently, a growing interest in many scientific areas that study the diverse applications of
marine compounds has been found, justified by their large biodiversity and simplicity of the extraction
and purification processes [1,2]. Marine biomaterials have wide applicability in biomedicine because
of their noncytotoxic characteristics, biodegradability and biocompatibility. These biological properties
have allowed the discovery of a broad range of novel bioactive compounds with pharmacological
properties and constitute a fundamental cornerstone of the pharmaceutical industry [2–4]. Some of
these compounds have been studied for cancer treatment due to their antitumoral properties [5–7],
among which are polypeptides extracted from tunicates [8] and sponges [9]. Many of these compounds
are already used clinical trials, such as Aplidin [10] and Ecteinascidin 743 [11].
Marine polysaccharides are mostly used in food and cosmetic industries, but are also widely
present in pharmaceutical sciences, with an increasing interest in integrating them as materials for the
incorporation of bioactive agents [12]. Marine algae are the main source of marine polysaccharides, but
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they can also be obtained from animal sources, such as the skeletons of crustaceans and cartilaginous
fish tissue. There are also some polysaccharides that can be extracted from marine microorganism,
like some prokaryotes [13]. Marine polysaccharides can be described as a large complex group
consisting of different macromolecules with different biological properties [14,15]. Polysaccharides may
exhibit different chemical structures and different biological properties such as biocompatibility,
biodegradability, adhesive properties and the ability to form hydrogels. Among the many marine
polysaccharides there is one group that stands out: sulfated polysaccharides [16]. In comparison with
other marine polysaccharides, they exhibit bioactivities that include antioxidant [17], anticoagulant [18],
anticancer [19], antiviral [20], anti-allergic [21], anti-adhesive, anti-angiogenic and anti-inflammatory
actions [22]. The systematic study of some of these materials for drug delivery systems (DDSs) allowed
discovering new chemical modification methods aiming to harness such biological activities and
change their affinity to specific drugs. Considering the latter, it has been possible to increase the ability
to incorporate drugs and increase the efficacy of their release, either by chemical reactions or by
interactions with other natural or synthetic polymers [23].
The interest in the study of marine polysaccharides for DDSs with therapeutic purposes relies
in the possibility of developing novel approaches of less invasive and more personalized treatments.
Several experiments have already shown that many of these biomaterials allow loading lower drug
dosages, which may lead to a drastic reduction of the side effects caused by the drugs. These materials can
be used as a signaling marker that could lead the delivery of a carrier to a specific location and widening
the function of DDSs as diagnostic instruments [24,25]. These systems also have a wide applicability in
gene therapy, which is usually limited by the health risk of associated with viral vectors [26]. In contrast,
biomaterials have been shown to offer numerous advantages for the encapsulation of genetic material
and others therapeutic agents, by ensuring stabilization and protection, also increasing its solubility and
promoting a sustained release as well their biocompatibility and in some cases biodegradability [27,28].
In this review, we focus on the use of marine polysaccharides as raw materials for the construction of
DDSs (Figure 1).
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We identified alginate, chitosan, carrageenan, hyaluronan (also known as hyaluronic acid) and
chondroitin sulfate as the major marine polysaccharides used currently in—or being considered
for—the pharmaceutical industry. The various means to modify and adapt these biopolymers to
achieve drug protection and delivery, stimuli-responsiveness and targeting capability will be discussed.
2. Polysaccharides from Marine Algae
Among the vast marine organism diversity, algae are the main source of marine polysaccharides.
There are some polysaccharides that can be extracted from marine prokaryotes like microalgae,
which can also be grown in bioreactors under controlled conditions. Red macroalgae are the most
used sources of polysaccharides but it is possible to obtain polysaccharides from green or brown
macroalgae. Seaweeds are a different type of multicellular marine algae and are also a major source of
polysaccharides. The latter are also divided in groups: red, green and brown. Nowadays, the large
quantity of marine algae that reach and deposit in coast regions has led to a widespread use of marine
compounds to produce cosmetics, and food supplements and emulsifiers, among others. Despite their
large bioavailability, polysaccharides remain relatively unexploited in the medical industry. Figure 2
represents the main polysaccharides that will be discussed herein.
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2.1. Alginates
Algi te is a polys ccharide extr cted from brown seaweeds, including Laminaria hyperborea,
Laminaria digitata, L minaria japonica, Ascophyl um nodosum, and Macrocystis pyrifera [29]. It is composed
by a sequenc of two (1Ñ4)-linked α-L-guluro ate (G) and β-D-mannuronate (M) monomers (Figure 2).
The proportion of M and G blocks may vary with the type of seaweed that it is extracted from.
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For example, alginate extracted from Laminaria digitata and Ascophyllum nodosum have been shown to
have M/G ratios of 1.16 and 1.82, respectively [30]. Alginate is biocompatible, has low toxicity and
high bioavailability as well. These are the main advantages that make alginate one of the biopolymers
with the widest biomedical applicability. One of the most common applications of alginate is their
use as an excipient in DDSs, namely acting as a stabilizer agent in pharmaceutical formulations [31].
Alginate has carboxyl groups which are charged at pH values higher than 3–4, making alginate soluble
at neutral and alkaline conditions [32]. Such pH sensitivity promotes greater protection for drugs with
preferential absorption in the intestinal tract: the acidic environment of the stomach does not disturb
the stability of the alginate carrier, whereas in the intestine (where the pH is alkaline) the solubility of
this biopolymer—as well as the drug release—is promoted [33]. Thus, solubility and pH sensitivity
make alginate a good biomaterial for the construction of DDSs [34].
Alginate is widely used for its biocompatibility, low toxicity, high bioavailability, lower extraction and
purification costs as compared with other biopolymers, and for the capability to be processed in the form of
hydrogel matrices, beads and particles [12,35–37]. Alginate is also used as an excipient in pharmaceutical
tablets to promote greater protection and stabilization of the drug. Sodium alginate is the type of alginate
mainly used in the pharmaceutical industry in the manufacture of tablets, especially when the drug is
not soluble in water. Sodium alginate may be used for the purpose of extending the drug release [31].
Studies using tablets containing ibuprofen demonstrated that it is possible to control the absorption
ratio of the tablets. By using sodium alginate with different chemical structure and degree of viscosity,
Sirkia et al. obtained carriers that triggered either an immediate ibuprofen release or prolonged it,
proving that the chemical structure of alginate may influence the release rate of the bioactive agent [38].
In acidic environments, alginate carboxyl groups are protonated, i.e., in the –COOH form, being
thus uncharged and exhibiting higher viscosity [32]. This may interfere with the elution of the bioactive
agent from the device, thereby limiting drug release when the pH is low [39–41]. However, gelling
sodium alginate with Ca2+ ions can solve pH dependent limitations related to the hydration, dilation
and erosion of the carrier. Alginate has the ability of cross-linking with Ca2+ ions through an ionotropic
gelation process, usually above pH 6 [42]. Ca2+ is not the only ion capable of promoting ionotropic
gelation of alginate: Ba2+ or Zn2+ ions may also be used for that propose [43]. Virtually any drug may
be entrapped during such mild cross-linking process, and its subsequent release may be dependent
on several factors, such as cross-linking extension [44]. Giunchedi et al. reported that using sodium
alginate, hydroxypropyl methylcellulose (HPMC), calcium gluconate, and ketoprofen as a model
drug in the preparation of tablets by direct compression in different combination and ratios may
prolong drug release, in particular in tablets with 20% of HPMC [45]. Alginate hydrogels also have
applications in wound healing treatments through the construction of structures used for wound
dressings. Several studies show that the bioavailability of drugs encapsulated in alginate hydrogels
is greater than if free drug was applied directly at the lesion site, thus increasing the efficacy of
healing [46]. Alginate hydrogels are also used widely in tissue regeneration treatments and cell
encapsulation [47,48]. Hydrogels obtained from alginate, in particular, present some similar features
of the extracellular matrix, thus being appropriate materials to be used in tissue engineering and
regenerative medicine applications [46]. However, it should be noted that the gelling capability of
alginate varies with the proportion of G and M groups, with alginates rich in G content yielding higher
strength when compared to alginates rich in M groups [49].
Alginate is also used in the construction of microparticles with the ability to incorporate different
bioactive agents, particularly proteins. Alginate microparticles have the capability of retaining large
amounts of drug and also promoting protection of the cargo from any proteolytic attack. There are
different mechanisms of release of a bioactive agent from the carrier, such as through variations of
temperature and pH, and the use of biodegradable materials or enzymatic degradation, among other
chemical and physical stimuli-responsive methods [32,33,35,50]. These parameters are difficult to
control and program, since they can vary significantly. However, new release mechanisms from
microparticles have been developed, that depended on fully controlled external stimuli, such as
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ultrasound-triggering. Duarte et al. developed a type of alginate microparticles which were shown to
have perfluorocarbon breakthrough capacity when subjected to vibration by ultrasound waves [51].
Results showed a disruption of these microparticles after 15 min of exposure, suggesting that such
structures are promising DDSs controlled externally by acoustic stimuli (Figure 3).
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Over the years, other methods have been developed to fabricate rug delivery particles that
promote a better loading efficacy of bioactive substances. Using superhydrophobic surfaces it is
possible to produce polymer particles suitable as DDSs. This method allows loading drugs into
spherical structures with an encapsulation efficiency close to 100% [52–54]. Another strategy to
synthesize p rticles relies on c mplexation, based on the electrostatic interactions between alginate
at neutral and alkaline pH values, bioa tive agents and oth r kind of naturally occurring polymers,
such as the polycation chitosan [23,31,33,47]. In this matter, alginate complexes have been used to
construct DDSs (especially nanoparticles) for gene therapy treatments. The very first systems for the
gene delivery were based on genetic material encapsulated within viral vectors. These have several
limitations such as the possibility to trigger an immune and inflammatory reactions, infections and
mutations. These systems also have high c sts of production due to complexity in the processing of
viral vectors [26]. Taking advantage of the capability of n tural polymers to f rm complexes with
DNA, safer DDSs could be synthesized to deliver genetic material. The most commonly used polymers
in the construction of DNA load vehicles are usually of synthetic origin, for example polyethylenimine
(PEI), poly-L-lysine (PLL), poly(L-ornithine) and poly(4-hydroxy-L-proline ester) [55]. The use of these
synthetic materials has allowed the synthesis of complexes via electr static interacti ns between the
polymer nd the DNA, allowing e creation of a stable complex and the possibility of size adjustment.
One of the major limitations of using synthetic materials is their often adverse biological effect in the
body. PEI, for example, exhibits elevated levels of cytotoxicity [56]. In contrast, most natural materials
are biocompatibile, biodegradable (in some cases) and show similar capacity to form ionic bonds,
therefore providing ensuring good protection for genetic material [57–59]. Krebs et al. developed
a calcium phosphate-DNA nanop rticle system incorpora ed in algi ate-based hydrogel for gene
delivery to promote bone formation. Results showed a DNA sustai ed release from the lginate
hydrogel around 45% of DNA released after approximately 75 days. In vivo studies, through the
injection of alginate hydrogels containing calcium phosphate nanoparticles and osteoblast-like cells in
mice, showed evidence of bone formation [60].
Taking its anionic nature, alginate can be assembled with polycations as structures other than
particles using l ye -by-layer (LbL). LbL is used to fabricate ultrathin nanostructured films in multilayer
fashion based on complementary interactions between building blocks, such as polyelectrolytes [61–63].
This technique may be useful as a biomimetic approach applied in deconstructing and reconstructing
the physiological conditions found in native biological environments, such as the human body [64].
Polyelectrolyte freestanding films (i.e., films with a few micrometers in thickness) have been shown
to be suitable drug reservoirs of biomolecules, such as growth factors and antibiotics [65]. This type
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of films exhibit a good cell adhesion, possibility of cargo entrapment and fast release by variations
of electrostatic interactions strength, and also promote a sustained release due to the slow film
degradation [66–70]. Such multilayer systems can be also used as barriers with controlled mass
transporter properties [71]. The versatility of LbL allows it to be extrapolated to the third dimension to
conceive more complex DDSs, such as spherical capsules and tubular structures [72].
Microcapsules are also typical shapes of alginate processing following different techniques,
including emulsion [73–75], multiple-phase emulsion [31,76] and calcium cross-linked encapsulation [77].
The ability of alginate to create complexes with other biomaterials by electrostatic interactions,
chemical modification or cross-linking can be exploited for building hybrid and more versatile DDSs.
Capsules constructed from chitosan/alginate-PEG complexes are reliable models for encapsulating
proteins, such as albumin, one of the most common model proteins used in controlled release
studies [78]. The construction of alginate spherical structures with other types of synthetic materials
can be a good strategy to extend the versatility of these systems. Using poly(N-isopropylacrylamide)
(PNIPAAm) to take advantage of its thermosensitive properties [79] in combination with alginate
can lead to devices capable of delivering biomolecules with a dual stimuli-responsive dependence
(both pH and temperature) [80]. Studies using indomethacin as a model drug reported that
chitosan-alginate-PNIPAAm beads showed lower release rates with decreasing temperatures [81].
The same occurs when there is a decrease in pH, indicating that it is possible to control the permeability
of the particles by controlling both pH and temperature. This approach can lead to the development of
DDSs capable of promoting higher control over the release of drugs, proteins and others biomolecules
with pharmaceutical interest. Following a similar concept of polymer conjugation, alginate can also
undergo complexation with natural polymers, like chitosan, to enhance the absorption and cargo
protection in oral delivery, for example, for the administration of insulin [73,82].
Alginate may be used in the construction of capsules for cell encapsulation often associated with
cytotherapy treatments or simply the creation of cellular microcultures in more complex systems where
the use of a conventional bioreactor is not possible. In this context, a new approach to the construction
of alginate-based capsules for the incorporation of different types of cells has been presented [83,84].
Cells were encapsulated in alginate liquefied particles, coated with multilayer of alternating chitosan
and alginate. Along with the cells, poly (lactic acid) microparticles were co-encapsulated to provide
anchorage points so that cell survival is promoted. Results demonstrated a high viability of the
encapsulated cells and usefulness of these capsules as culture systems. This type of system has wide
applicability not only for the cell culture but also in other biomedical applications, since it will allow the
encapsulation of different types of cells in combination with other biomolecules such as, for example,
growth factors and other cytokines.
2.2. Carrageenans
Carrageenan is a sulfated polysaccharide present in red algae, which structure consists in a linear
sequence of alternate residues forming (AB)n sequence, where A and B are units of galactose residues.
These residues may or may not be sulfated. They are linked by alternating α-(1Ñ3) (unit A) and
β-(1Ñ4) (unit B) glycosidic bonds (Figure 2). Unit A is always in D- conformation, while unit B
can be found either in D- or L-configuration. The sulfated groups give it a negative charge, which
categorizes carrageenans as polyanions [85]. Carrageenans are classified according to their degree of
sulfation: they can be kappa (κ), iota (ι), and lambda (λ), if they have one, two or three sulfate groups
respectively. The extraction process is straightforward, consisting in the immersion of the raw material
in alkaline solution so that a gel forms. Then follows an extraction step, where the gel is immersed
in water heated at 74 ˝C. Depending on the type of carrageenan and desired degree of purification,
it is possible to execute additional purification steps, such as dialysis. The process finishes with
filtration, precipitation and drying [85]. κ and ι types are most frequently extracted from algae of the
Kappaphycus and Eucheuma genera, while λ type is often extracted from algae belonging to the family
Gigantinaceae. The number of sulfated groups influences the gelation capability. Carrageenans κ and ι
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can form gels in the presence of cations, while the high sulfation degree of λ carrageenan prevent its
gelation. Gelation capability has been used in many areas, such as food industries (using carrageenan
as an emulsifier and stabilizer), as well as in the cosmetic and pharmaceutical industries [86].
Contrary to what happens with other biomaterials of marine origin, the use of carrageenan as
an excipient in the pharmaceutical industry is not common, thus reports about their applications,
characteristics and functions are infrequent. As an example, a study was conducted where two types
of carrageenan (κ and ι) were analyzed in terms of compression behavior and their capability of
tablet formation [87]. Results showed that both carrageenans are suitable excipients for controlled
release. Carrageenans are also present in various biomedical applications due to their anticoagulant
properties [88], antitumor, immunomodulatory [89], anti-hyperlipidemic [90] and antioxidant
activities [91]. They also have a protective activity against bacteria, fungi and some viruses [92,93].
Due to the latter, carrageenans have been suggested for possible treatments of respiratory diseases,
such as the famous bird flu, and is also being tested for killing other viruses, such as the dengue fever,
hepatitis A, HIV [94] and herpes viruses [95]. Studies showed that carrageenan, and derivatives of
degradation have different levels of toxicity, but do not endanger the health of the patients [93,96].
These properties make carrageenan a promising biomaterial for biomedical applications.
The use of carrageenan as an excipient in the manufacture of devices for oral delivery depends
mostly on their physicochemical properties, such as water solubility and jellification capability.
Carrageenan load capacity depends largely on the sulfation extent, which affects its mechanical
properties and its dissolution rate. These factors may affect the release of the cargo, prolonging
or accelerating its release [97]. A greater control over the drug release profile—regardless of other
conditions, such as carrageenan type and pH—is possible by association or conjugation with other
polymers. The addition of polymers such as hydroxypropyl methylcellulose (HPMC), a temperature
sensitive semi-synthetic polymer, can solve problems related to pH erosion and provide higher
protection to the drug, thus promoting a sustained release that does not depend on pH [98]. However,
the opposite response may be desired (i.e., pH-triggered degradation) and, for that, pH responsive
polymers may be conjugated. By varying the pH, it is possible to control not only the loading but
also the release mechanisms of carrageenan/alginate interpenetrated networks [99]. The use of
stimuli-responsive materials offers another perspective for drug and gene delivery where the carrier
may be an active trigger and function as a therapy optimizer. Using temperature-sensitive materials for
nanocarriers construction can promote a controlled release at temperatures above 37 ˝C. Such a system
could be helpful in situations as common as a fever. However, it is possible to use other nanocarriers
in situations of hyperthermia, where the drug would be available in a localized region [100,101].
Carrageenan in the pharmaceutical industry is generally used as a raw material for the construction
of DDSs, cell capsules for cell therapies and cartilage regeneration applications [27,102]. The use of
carrageenan-based hydrogels as a vehicle for the controlled delivery of biomolecules can be a good
strategy especially for cargo stabilization Popa et al. showed that κ-carrageenan hydrogels are adequate
environments to encapsulate different types of human cells achieving chondrogenic differentiation [103].
This system proved to have potential for cartilage regeneration strategies, not only due to the referred
differentiation but also because these hydrogels can be easily injectable in situ and may be used as
reservoirs for growth factors [104]. Carrageenan-based hydrogels, along with other materials of marine
origin, have also proved to be suitable good devices for cell encapsulation [105,106]. New methods on the
production of spherical beads and fibrillar carrageenan/alginate based hydrogel have been developed.
Fibrillar hydrogels obtained by wet spinning showed great potential for applications as a cell carrier
for cell delivery systems [107]. Knowing the biological properties of carrageenan, it is hypothesized
that carrageenan-based devices are suitable DDSs for the delivery of not only bioactive agents but also
of cells for cytotherapies.
Taking advantage of the polyanionic nature of carragenans, they can be combined with polycations
via electrostatic interactions. Grenha et al. developed carrageenan/chitosan nanoparticles through
a simple construction method by ionic interactions between polycationic groups of chitosan and
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polyanionic ones of carrageenan (Figure 4A) [108]. This method has the advantage of avoiding the
use of organic solvents and harmful cross-linkers. These nanoparticles had a diameter size between
350 and 650 nm. Using albumin as a model protein, in vitro release tests demonstrated a prolonged
release over time, with a 100% of albumin release after three weeks (Figure 4B). Having a slow release
rate is important since it enables the reduction of the encapsulated dose and also provides continuous
long-term release without the need for repeated administrations. Cytotoxicity tests demonstrated that
these devices present low toxicity. These results are a good indicator that these structures may be
feasible for the encapsulation of agents with therapeutic purposes. Carrageenan has also been used in
the construction of multilayer structures [109], microcapsules [110] and micro/nanoparticles [111].
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2.3. Fucoidans
Fucoidan is a sulfated polysaccharide found in many species of brow algae. It is a polymer
chain of (1Ñ3)-linked α-L-fucopyranosyl residues (Figure 2), although it is possible to find alternating
(1Ñ3) and (1Ñ4)-linked α-L-fucopyranosyl residues. The structure of fucoidan and its composition
depend largely on the extraction source, especially the type of algae. For example, fucoidan extracted
from Fucus vesi ulosus is rich in fucose and sulfate, whereas that obtained from Sargassum stenophyllum
contains many more types of residues besides fucose and sulfate, such as galactose, mannose,
glucuronic acid, glucose and xylose. A more detailed comparison between several fucoidans and their
extraction sources can be foun elsewhere [112]. The extraction can be processed by precipitation
using salts or o ganic so ve t , followed by a purification step by chromatography. Recently it was
reported that fucoidan has antitumor activity dependent on the degree of sulfation and can inhibit
tumor cell proliferation and growth [113,114]. However, fucoidan may have inhibitory effects over
some cellular functi ns. Cumashi et al. demonstrated that fucoidans may exhibit strong antithrombin
properties and suppresses tubulogenesis on HUVECs [22]. Fucoidan has also shown anticoagulant
and anti-inflammatory properties, as well as anti-adhesive and antiviral properties [115,116].
Like other marine polysaccharides, fucoidan can also be used as a raw material for the construction
of DDSs. A typical way of processing fuc idan DDSs is by electr static interactions with chitosan,
to make microspheres, so-call d fucosph res [117], which have been suggested for burn treatments.
Particles with sizes ranging between 367 and 1017 nm were shown to trigger both in vitro and in vivo
a decrease of the normal burn treatment time due to the increase of regeneration and healing of epithelial
tissue [118]. Taking a vanta e of the gre t bioactivity of fucoidan, and th bility to complex with
other materials like c itosa , other approach s c b pursued. Hu g and Li developed novel
chitosan/fucoidan nanoparticles with antioxidant properties for antibiotics delivery (Figure 5A) [119].
These nanoparticles presented a spherical morphology and diameter of 200–250 nm. Results showed
a highly anti-oxidant effect by reducing concentration of reactive oxygen spices (ROS), using gentamicin
as a model drug, release studies showed a controlled release around 99% of gentamicin in 72 h (Figure 5B).
The antioxidant chitosan/fucoidan nanoparticles could thus be effective in delivering antibiotics to
airway inflammatory diseases, where the amount of ROS it significantly high. Another approach to
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take advantage of chitosan/fucoidan interactions as DDSs is to synthesize hydrogels, as described
by Nakamura et al. The authors developed a chitosan/fucoidan microcomplex hydrogel for the
delivery of heparin binding growth factors, which showed high affinity with growth factors and were
able to promote growth factor activity and also a controlled release [120]. In vivo studies showed
a neovascularization promoted by the growth factors released from the chitosan/fucoidan hydrogel.
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Another shape that can be obtained resorting to the polyanionic character of fucoidan are
capsules, processed by LbL, particularly fucoidan-chitosan pH sensitive capsules for insulin controlled
release [121]. Pinheiro et al. used polystyren nanop rticles with a diameter approximately 100 nm as
a templa e for the d positi n of a fucoida -chitosan multilayered coating [122]. Aft r construction of
the coating, the polystyrene core was removed, being thus possible to incorporate into the capsule
numerous bioactive agents. Using PLL as a model molecule, results showed that the release profile
was pH dependent and also that the release occurred by diffusion. These results indicate the sensitivity
of these particles to pH variations found along the gastro-intestinal tract and the possibility of using
these particles as DDSs for oral administration.
2.4. Ulvans
Ulvan is a sulfated polysaccharide extracted from the green algae of the Ulva and Enteromorpha
genera. Ulvan consists in a polymer chain of different sugar residues like glucose, rhamnose, xylose,
glucuronic and iduronic acid with α- and β-(1Ñ4) linkages (Figure 2). Because of the large number of
sugars in its composition, ulvan may exhibit variatio s i the electronic density and c arge distribution,
as well as variations of molecular weight. Since it contains rare sugars, ulvan is a natural source for
obtaining them upon depolymerization, instead of resorting to chemical synthesis. The extraction process
is simple, consisting in adding an organic solvent over the feedstock followed by successive washing steps
with hot water, filtration and centrifugation [123]. Ulvan has several properties of biological interest, such
as exhibiting antiviral, antioxidant, antitumor, anticoagulant, anti-hyperlipidemic and immune system
enhancing activities. Ulvan also presents low cytotoxicity levels in a wide range of concentrations [124].
Ulvan is typically used in the food and cosmetic ind stries, but becaus of their biological p operties,
it has a great potential for the development of new DDSs, such as being used as an active principle in
pharmacological formulations [125]. Because of their ability for complexing with metal ions, ulvan can
also be used as a chelating agent in the treatment against heavy metal poisoning [126]. Furthermore,
the capacity to process ulvan as nanofibers and membranes has been useful for tissue engineering and
regenerative medicine, for example in wound healing treatments [127].
Ulvan has been used in construction of nanocarriers for biomolecules. Alves et al. constructed
a two-dimensional ulvan-based structure for drug delivery by chemical cross-linking for wound
healing [128]. Using dexamethasone as a model drug, there was a rapid release in the first hour
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(around 49%), followed by a slower and sustained release, around 75% up to 14 days. Additionally, it
is also possible to obtain three-dimensional ulvan-based structures. In this context, ulvan/chitosan
particles were produced for the encapsulation and release of dexamethasone [129]. These particles were
incorporated in three-dimensional poly (D,L-lactic acid) porous scaffolds for bone tissue regeneration.
In vitro release assays demonstrated a fast release in the first three hours (around 52%), followed by
a sustained cumulative release up to 60% in the next 21 days.
Like other marine polysaccharides, ulvan may undergo chemical modifications to synthesize
thermostable hydrogels. The addition of other functional groups is also possible so that temperature
and light responsive hydrogels are conceived. In this case, ulvan was modified with methacrylate
groups to allow jellification by photopolymerization through the irradiation with ultraviolet light [130].
This is a useful approach to develop cell encapsulation strategies for cytotherapy applications. Ulvan is
also used in the construction of membranes, due to electrostatic interactions with other cationic
polymers [131]. Through chemical modification, ulvan and chitosan can also be used as a polymeric
component of bone cement, especially due to their mechanical properties [132].
3. Polysaccharides from Marine Animals
There are other marine sources beside algae and microorganisms: marine animals are also an excellent source
for polysaccharides. In this section, the most important animal origin polymers used in DDSs will be presented.
There are two main categories of polymers: chitin-derived polymers and glycosaminoglycans (GAGs).
3.1. Chitosans
Chitosan is a linear polysaccharide derived from chitin, one of the most abundant natural polymers
of our ecosystem [133]. Chitosan is obtained by the deacetylation of chitin, resulting in a compound
with randomly distributed D-glucosamine residues (deacetylated unit) and N-acetyl-D-glucosamine
(acetylated unit) (Figure 2) [134,135]. Chitosan, as well as chitin, can be degraded by enzymes such
as chitinase and lysozyme [136]. Chitin is the main component of the exoskeleton of arthropods
and crustaceans such as crabs, shrimps and lobsters, and can also be extracted from some fungi and
nematodes. Chitin is not water soluble, and thus it is usually converted into soluble derivatives
including chitosan (soluble in acidic conditions) and carboxymethyl chitosan (soluble in a wide range
of acidic and alkaline solutions). Chitosan has amine groups sensitive to pH variations, being positively
charged in acidic environments and neutral in alkaline pH values (pKa close to 6) [32]. Chitosan is one
of the marine polysaccharides most widely used and studied for biomedical applications, in particular
in the construction of nanoparticles, beads and capsules for controlled drug delivery systems, and also
membranes, films and scaffolds for tissue engineering and regenerative medicine [137–140].
Chitosan has antimicrobial activity, a useful property to build films that prevent wound infection [141,142].
It also shows antitumor and anti-inflammatory activity [143,144]. All of these biological properties
make chitosan an excellent candidate for constructing devices that require the contact with biological
environments, and as excipients for DDSs [145,146]. For chitosan-based DDSs, electrostatic interactions
between the polysaccharide and a bioactive agent are a key to drug stabilization, protection and
acceleration (or deceleration) of its release. This means that, if a drug is anionic, positively-charged
polymers (like chitosan) are used as excipient, and vice-versa. The release profile and rate of biomolecules
from within chitosan-based carriers may depend on the morphology, size, density, cross-linking degree,
as well as the deacetylation degree of chitosan and physicochemical properties of the bioactive agent.
The release will also be affected by the pH and by the presence or absence of enzymes. The release
may occur in different ways: (i) release from the surface of DDSs; (ii) passive diffusion; and (iii)
erosion of the DDS. Deacetylation degree of chitosan can be also used as a degradation control
parameter [137,147]. Another mechanism of release exploited for chitosan-based carriers is triggered
by enzymatic degradation [148].
It is also possible to increase the binding capacity of poorly water-soluble drugs by introducing
different chemical modifications onto chitosan. Chitosan chemical modification can be a good strategy
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to increase the effectiveness of release and attribute other properties such as drug protection and
stabilization [135]. Hydroxypropyl chitosan (HPCH), obtained from the reaction between chitosan and
propylene epoxide under alkali condition, can be grafted with carboxymethyl β-cyclodextrin mediated
via a water-soluble 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) [80]. Hydrophobic drugs
can be encapsulated due the presence of hydrophobic groups present in HPCH. In addition, due to
the free amine groups that can be protonated at lower pH values such DDSs can be pH-responsive.
Using ketoprofen as a hydrophobic drug model, in vitro release results showed that this chitosan
derivate has a great potential as a biodegradable delivery system for hydrophobic drugs in a pH-sensitive
controlled release [149,150]. The introduction of thiol groups has also been shown to increase
the solubility of chitosan in water, maintaining the pH dependence of chitosan particles [151].
N,O-carboxymethyl chitosan (NOCC, also known as carboxymethylated chitosan) is a water soluble
derivative that retains a fraction of the amine residues and its polycationic properties under acidic
conditions [34]. Ketoprofen-loaded beads of NOCC and a PNIPAAm with a telechelic amine group
(PNIPAAm-NH2) were developed for the study of controlled release system. Release studies taking
in acidic and physiological conditions at 21 and 37 ˝C showed that these particular beads are
sensitive to temperature and pH variations [152]. Acetylated chitosan grafted with fatty acid like
palmitoyl is another strategy to develop chitosan-based excipients to entrap and release hydrophobic
drugs [153–155]. Photo-sensitive products can also be synthesized. Methacrylamide chitosan,
a water-soluble modified chitosan, is suitable for photo-cross-linking and has been used for the
construction of delivery carriers. Wijekoon et al. developed a fluorinated methacrylamide chitosan
hydrogel for oxygen delivery in wound healing [156]. During the methacrylation process, different
fluorinated ligands were added to chitosan to obtain different fluorinated methacrylamide chitosans.
Hydrogels were constructed by photo-cross-linking. This new biocompatible, injectable moldable
photo-cross-linked chitosan-based hydrogel allowed controlling both the capacity and rate of oxygen
delivery, maintaining beneficial oxygen level up to five days.
The reactivity of chitosan with other materials may also promote sustained release, as well as cargo
stabilization and protection. This can be achieved using different methods, such as graft copolymerization
with synthetic polymers like poly(ethylene glycol) (PEG) and PEI [148,157]. Several studies showed the
ability of chitosan to enhance and prolong the absorption of hydrophilic drugs taken by oral [158]
and pulmonary [159] administration routes. Chemical modification of chitosan with PEG is a way
of improving the biocompatibility of chitosan, especially to reduce chitosan toxicity, as well as to
enhance protein adsorption, cell adhesion, growth and proliferation [160,161]. Prego et al. showed
that chitosan-PEG nanocapsules for oral delivery of peptides exhibited low cytotoxicity and enhanced
intestinal absorption capability [162]. Other studies showed that this approach can also be applied
to deliver other drugs such as insulin [163–166]. Taking advantage of the jellification capability of
some copolymers containing chitosan, Bhattarai and coworkers presented an injectable PEG-grafted
chitosan hydrogel for controlled release [167]. These hydrogels were liquid at room temperature and
a gel at physiological temperature. Using albumin as a protein model, in vitro release studies at 37 ˝C
showed a high release in the first 5 h, up to 50%–60% followed by a sustained release for the next days
with a cumulative release up to 80%.
Hydrogels based on cross-linked chitosan may have the ability to promote a sustained release upon
nasal administration. Hydrogels were constructed by joining N-[(2-hydroxy-3-trimethylammonium)
propyl] chitosan chloride (HTCC) and PEG with the addition of a small quantity ofα-β-glycerophosphate
(α-β-GP) as a gelling agent [168]. These hydrogels are pH sensitive and have the particularity of being
liquid at room temperature and exhibit higher rigidity at 37 ˝C. Wu and coworkers developed these
hydrogels as smart devices for the controlled release of biomolecules through nasal administration as
drops or spray. Once applied, the solution is exposed to physiological temperature, becoming a viscous
hydrogel which can be absorbed by mucosa. Because of their ease of production and administration,
this new formulation was tested as a loading device for the controlled release of insulin. Assays in
rats showed an increased absorption in the nasal cavities and a decrease in blood glucose, without
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any evidence of cytotoxicity. These results demonstrated the great potential of these hydrogels as
carriers for the controlled release of bioactive agents, especially hydrophilic biomolecules [169].
Nasal administration is less compliant for the patient, causing no discomfort and pain, leading
to a reliable management and patient satisfaction [170]. Furthermore, the fact that this type of hydrogels are
liquid at room temperature also enhances their ease of application as a DDS for parenteral administration [171].
Chitosan can form stable and highly dense electrostatic complexes capable of providing stability
and protection to drugs. Being a polycationic polysaccharide, chitosan can form particle complexes
with nucleic acids for gene therapy [172–175]. The formation of particle complexes between the
polymer and the nucleic acids depends on many intrinsic factors, such as the deacetylation degree, the
molecular weight, as well external factors like temperature and pH, and represent crucial factors on the
efficiency of transfection [176]. The positive charge of chitosan allows interacting with the negatively
charged peptidoglycans present in the cell membrane, facilitating the entry of a chitosan/DNA complex
into the cell by pre-established endocytic pathways [177,178]. The amount of genetic material available
to react with chitosan is also very important: an improper ratio can lead to the dissociation of the
complex or to a lack of synthesized complexed particles, resulting in low transfection rate [176].
It has been reported that using chitosan overcomes some of these limitations: chemically modifying
chitosan can increase the affinity with the DNA to yield a more stable complex, which can lead to
an increase in the transfection efficacy [179]. The modifications can also increase chitosan solubility
and thus offer greater protection to the cargo from the degradative action of DNases on DNA [176].
Chemical derivatives opened a new range of possibilities to construct DDSs for the intracellular
release of the genetic material, with wide applicability in the treatment of various genetic diseases.
Following this line, Forrest and coworkers presented a PEI-PEG-chitosan-copolymer for gene delivery
with good loading capacity and high transfection efficacy, as well as low toxicity that makes these
particles good candidates for in vivo gene delivery [180].
Chitosan-based capsules can also be synthesized resorting to electrostatic complexation, and, in
some cases, are able to respond to external stimuli other than pH. One such example is the conception
of LbL microcapsules made by complexation of chitosan with negatively charged elastin-like
recombinamers (ELRs), recombinant polypeptides with intrinsic response towards temperature [181].
Novel thermoresponsive ELR/chitosan microcapsules were developed for the delivery of active
molecules [182]. Using bovine serum albumin (BSA) as a model molecule, the results showed a greater
BSA retention at physiological temperature (37 ˝C), when compared to room temperature (25 ˝C).
Studies with cells also showed a low cytotoxicity for such structures. The pH response of these
microcapsules was not studied, but the results are a good indicator that chitosan can bond with
other sources of stimuli-responsive biomaterials, including unconventional ones such as genetically
engineered polypeptides. While thermal responses are perhaps the most exploited mechanism
integrated in smart DDSs, it is debatable whether their sensitivity would be enough to treat, for
example, a common fever, where the body temperature varies just 1–2 ˝C. Besides, not all people have
exactly the same body temperature. Therefore, conjugating two or more physiological parameters could
be a solution for diseases that require administration based on triggers operating within tight ranges.
3.2. Hyaluronans
Hyaluronan belongs to the family of glycosaminoglycans. GAGs are linear, negatively charged
heteropolysaccharides composed of repeating disaccharide units of N-acetylated hexosamine and uronic
acid (with the exception of keratan sulfate) [183]. It is a linear polysaccharide consisting of an alternating
chain disaccharide units of N-acetyl-D-glucosamine and D-glucuronic linked by β-(1Ñ3) and β-(1Ñ4)
glycosidic bonds (Figure 2) [184]. Hyaluronan is a major component of extracellular matrix and is present
in the synovial fluid, vitreous humor and cartilage tissue. Due to its high viscoelasticity, hyaluronan
has an important role in several biological functions and also as an excellent material for different
biomedical applications. Namely, it is involved in tissue regeneration, cell proliferation, differentiation and
migration [185]. Because of its presence in the synovial fluid in joints, hyaluronan can be used as a biological
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marker to diagnose diseases associated with rheumatoid arthritis [186]. Due to its biocompatibility and
biodegradability, hyaluronan has also been proposed for tissue engineering applications for manufacturing
wound healing structures [187] and as a supplement for patients with arthritis [185]. Nowadays,
hyaluronan production is done on a large scale using different methods and sources, such as bacterial
fermentation [188–190]. hyaluronan may also be extracted directly from marine animal sources, such
as cartilage and also from the vitreous humor of several fish species [191]. His biodegradability is
mediated by the action of hydrolases, such as hyaluronidase, which breaks the glycosidic bond
between two residues [192]. In the human body, hyaluronan is present in various biological fluids,
allowing its use as a biomarker to monitoring its movement in biological fluids [193,194].
Hyaluronan hydrogels with dual stimuli-responsiveness can be made, namely towards pH and
temperature variations. Hydrogels were obtained from hyaluronan and PNIPAAm with TEMED as
a cross-linker [195]. Using gentamicin as a model drug, in vitro release assays at 37 ˝C and pH 7.4
showed an initial release of around 25% in the first 60 min, followed by a sustainable release up to
30% over the following 20 h. These results also showed that the release rate increases with increasing
hyaluronan ratio in the hydrogel composition. These structures showed sensitivity to variations in
temperature, showing potential as a device for biomolecules loading with smart controlled release
system. There are other interesting types of hyaluronan conjugate-based hydrogels. Hyaluronan-tyramine
(HA-Tyr) conjugates can be obtained by the enzymatic oxidative reaction of tyramine moieties using H2O2
and horseradish peroxidase (HRP). These hydrogels are highly biodegradable, which can be controlled
by the cross-linking degree [196], and can encapsulate drugs. It was reported that the concentration of
H2O2 has an influence in the mechanical strength of the hydrogel and on the release rate of drugs [197].
It was also reported that, in contact with hyaluronidase, the entrapped protein can be released
continuously and completely from a hydrogel due to the polymer network degradation. On the same
line of work, a new hyaluronidase incorporated-hyaluronan-tyramine hydrogel was developed for
the delivery of trastuzumab, an antibody drug against breast cancer. In vitro release studies showed
an antibody tunable release accompanied by the hydrogel degradation controlled by the concentration
of hyaluronidase, as well as trastuzumab-dependent inhibition on the proliferation on cells [198].
Like other polyanions, hyaluronan can be complexed with polycations such as chitosan to form
nanoparticles [199] and microspheres [200]. Recent studies presented these systems as a new approach
for the treatment of ocular disorders. Hyaluronan/chitosan nanoparticles have been synthesized by
means of electrostatic interactions to develop nanoparticles for the delivery of genes to the cornea
and conjunctiva [201,202]. Results indicated an appropriate size distribution (100–230 nm) and
internalization of these particles by endocytic processes mediated by membrane receptors. This result
reveals the great biomedical applications potential of these nanoparticles as gene delivery device for
treating diseases at the level of the human conjunctiva and other ocular diseases.
Hyaluronan has also been used as a coating material for spherical structures. Cross-linked chitosan
spheres can serve as templates for the alternating adsorption of hyaluronan and chitosan multilayers [203].
In vitro release using gentamycin sulfate as a model drug indicated a sustained release from the microspheres,
compared to the release from uncoated cores. These results show that a LbL coating can promote stabilization
to the cargo and for that reason allows an enhanced sustained release. Liposomes are also viable spherical
templates for hyaluronan coatings. Liposomes are pH sensitive lipid-based structures, and have been used
as carriers for the controlled release of bioactive agents for cancer treatments [204]. One useful application
of such pH sensitiveness is for the intracellular delivery of peptides. Jiang et al. presented a new
liposome coated with hyaluronan for anticancer drug delivery [205]. In this case, the coating protected
the liposome and the cargo against attacks by proteins present in the bloodstream. Entering the tumor
extracellular matrix, where the hyaluronidase degrades the outer layer of hyaluronan, exposes the
liposome to pH changes existing in the cytoplasm, enabling the intracellular drug release. A high
antitumor activity was also detected during in vivo tests.
One interesting feature of hyaluronan is the ability to interact with several proteins. Such capability
can be useful as a diagnostic tool, in particular due to existence of membrane receptors specific for
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hyaluronan. It is the case of CD44, a receptor that is highly expressed when there is an increase in cell
proliferation. Determining an increased expression level of CD44 by means of hyaluronan devices can
be an excellent marker for the early diagnosis of cancer [206]. Hyaluronan hydrogels can be used as
reservoirs of bioactive agents obtained via various methods of constructions [207]. Nanoparticles based
on the interaction of hyaluronan with metals, such as gold, have been widely used as markers for
diagnosing diseases such as rheumatoid arthritis and cancer due to the ability of some of these devices
to emit fluorescence [194,208–210].
3.3. Chondroitin Sulfates
Chondroitin sulfate is a sulfated glycosaminoglycan composed of a single chain of repeating
disaccharide units of glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) linked by β-(1Ñ3)
and can be sulfated in different carbon positions (Figure 2). It is usually extracted from the cartilage
of bovine and porcine cattle but can also be extracted from some marine animals, like the whale and
shark. However, due to ecological reasons, the extraction of protected species is currently quite limited.
There are nonetheless other non-mammalian marine animal sources, such as the ray, the salmon
fish, the sea cucumber, some cnidarians and mollusks [27]. Chondroitin sulfate has anticoagulant
properties and has been suggested as a natural substitute for heparin, one of the most widely used
anticoagulants [211,212]. In the pharmaceutical industry, this polysaccharide has been used as an active
principle in drugs with anticoagulant properties, as a supplement to prevent arthritis [213], and as
hydrogels for cartilage tissue regeneration [214]. Therefore, chondroitin sulfate is a suitable material to
build DDSs. Studies with chondroitin sulfate/chitosan nanoparticles have indicated a large retention
capacity of proteins and polypeptides, like growth factors [215]. Release assays showed a sustained
release of the cargo in the order of 65% in the first 30 days. Studies in vitro performed on human
adipose derived stem cells stem showed the ability of these nanoparticles to enter the cells promoting
osteogenic differentiation. Cell internalization proved to be dependent on the particles concentration
in the culture media, as well as on the incubation time.
Electrostatic interactions between different materials can be used for the construction of DDSs
with the ability to incorporate different bioactive agents, as well as to enhance the cargo loading and
to promote a sustained controlled release [216]. Despite the numerous advantages of using natural
materials, synthetic polymers are still commonly used in the pharmaceutical industry, though they can
be conjugated with natural ones. For example, chondroitin sulfate/PEG hydrogels was developed
and proposed for a variety of biomedical applications, such as in wound healing and regenerative
medicine [217]. This type of hydrogels proved to be biocompatible, since no inflammatory response
when implanted has been observed, and is also biodegradable by enzymatic activity.
While 3D hydrogels and spherical objects are common designs for DDSs, a recent study showed
that porous tubular structures can be constructed from hydroxyapatite and chondroitin sulfate for the
delivery of chemotherapeutics [218]. Results for doxorubicin hydrochloride release showed a high
encapsulation capacity around of 91% of efficacy due to the tubes geometry and porosity. In vitro release
assays at different pH values (5, 6, and 7.4) revealed a pH dependent controlled release. These results
revealed the potential use of these structures as controlled drug delivery devices for chemotherapy
treatments, not only because of their pH dependent release, but also due to the long-term sustained
release that eliminates the need for regular administration.
4. Emerging Glycosaminoglycan-Like Polysaccharides from Marine Origin
There are several types of glycosaminoglycans with different biological properties but, unlike
hyaluronan and chondroitin sulfate, their bioavailability is low, they are difficult to extract and to produce,
therefore they are not widely used in pharmaceutical sciences. However, due to their biological properties,
they can be used as active agents in supplements. Examples include the sulfated glycosaminoglycans
dermatan sulfate, heparan sulfate and keratan sulfate, and the nonsulfated agarose.
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4.1. Dermatan Sulfates
Dermatan sulfate is a glycosaminoglycan with a linear disaccharide chain containing units of
hexosamine, N-acetyl-galactosamine or glucuronic acid linked by β-(1Ñ4) or (1Ñ3). In some cases,
this compound may present residues of L-iduronic acid, being the main structural difference between
dermatan sulfate and chondroitin sulfate. Dermatan sulfate is extracted mainly from ray skin and can
be used as a stabilizer for growth factors and cytokines. Recent studies have shown anticoagulant
activity for dermatan sulfate without causing the possible complications present in the treatments
made with heparin [219–221]. Dermatan sulfate anticoagulant character inhibits thrombin, showing no
effect on factor X of the clotting cascade. It also has no interaction in platelet function. Thus, dermatan
sulfate is a good alternative for heparin [222]. Thanks to its anticoagulant and antithrombotic activities,
dermatan sulfate is seen as a potential substitute for heparin [211].
4.2. Heparan Sulfates
Heparan sulfate is another glycosaminoglycan which structure is very similar to heparin. It consists
in a linear chain of alternating D-glucuronic acid or iduronic acid and D-glucosamine residues, which
can be sulfated or acetylated. The distribution of sulfated residues can set some of the biological
properties of heparan sulfate. The number of sulfated groups can influence the affinity with other
proteins and so may influence their biological properties [223]. For example, heparan sulfate can block
DNA topoisomerase activity in cell nucleus [224], and also has a role in the control of cell cycle and
proliferation. Regarding the latter, heparin sulfate/cell complexes are often associated with increased
cell proliferation which can lead to processes of oncogenesis. Thus, heparan sulfate has a significant
role in the development of cancer, which is being associated with the increase of cell proliferation,
angiogenesis in tumors, cancer cells differentiation and metastasis formation [225]. However, the effect
of heparan sulfate on tumor cells may depend on the glycosaminoglycan structure, the type of tumor
cell and/or the tumor microenvironment [226].
Independently of its role in cancer, this sulfated polysaccharide is also biodegradable, particularly
by enzymatic action of heparanase [227]. Due to the presence of sulfated groups, it may bind to
a number of different proteins and regulate biological processes such as coagulation and regulation.
Heparan sulfate has the ability to bind to various polypeptides, such as the complex formed by the
cellular receptor and growth factors [228]. Chemical modification of heparan sulfate can interfere
with its anticoagulant activity and can have therapeutic effects in tumors. Regardless of the heavy
involvement of heparan sulfate in different stages of tumor formation, it is possible that this polymer
could be helpful as a new diagnostic method in the discovery and in the development of new drugs
for cancer treatments, as well as in the development of DDSs with sensing capability. [229]. Due to the
biological properties of heparan sulfate, it is not unreasonable to state that the production of heparan
sulfate-based DDSs based could be a strategic approach to develop new chemotherapeutic strategies.
4.3. Keratan Sulfates
Keratan sulfate is a glycosaminoglycan that lacks the uronic acid unit. The disaccharide unit normally
consists in galactose residues and N-acetylglucosamine bonded by β-(1Ñ4) linkages. The extremities
of keratan sulfate have a protein binding region at the extremities. There are three different classes of
keratan sulfate which differ in the nature of the protein binding region. Class I is known for its presence
in the cornea and in small cartilage. The protein binding occurs between the N- of a N-acetylglucosamine
and an asparagine. In Class II, also present in small cartilage, the protein binding is made between the
O- of N-acetylglucosamine with either a serine or a threonine. Finally, in Class III (first isolated from
nervous tissue), the protein binding occurs in the O- of the mannose residue to a serine or threonine [230].
The presence of keratan sulfate in corneal tissue is related to the maintenance of the moisture level of the
corneal tissue, which may influence its levels of transparency. Studies at the cellular level have shown
that keratan sulfate has anti-adhesive properties. In nervous tissues, keratan sulfate can prevent
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the growth of axons, and in cartilage it may decrease the immune response in diseases such as
osteoarthritis [231]. However, keratan sulfate presents an inhibitory action in nerve regeneration after
nerve injury [232,233].
4.4. Agarose
Agarose is a marine biomaterial with a structure similar to carrageenan, present in the cell wall of red
algae. Its structure comprises monosaccharide residues connected alternately in the conformation (AB)n.
The units consist of galactose residues linked by α-(1Ñ3) (unit A) and β-(1Ñ4) (unit B) linkages. The main
difference between carrageenan and agar is that the carrageenan unit A is always in the D- conformation,
while in the agar unit A can only be in the L- conformation [234]. Unlike carrageenan, agarose is not
classified according to the sulfation degree, since the best known type of agarose is a neutral type
without any sulfated group. Agarose is widely used in food industry and also in microbiology in
the form of gel to be used as culture medium in the form of agar. Agarose is associated with several
biomedical applications especially as hydrogels for the release of bioactive agents, taking advantage of
its ability to jellify, biocompatibility and native biodegradability [235,236].
5. Conclusions
Marine polysaccharides have been widely used to synthesize DDSs. The fact that they are
biocompatible, nontoxic and often biodegradable and stimuli-responsive makes these polymers suitable
raw materials for the construction of increasingly complex loading devices with a release that can be
potentially controlled. We showed that such devices can be constructed using different methods and can
be synthesized in various shapes, such as hydrogels, particles and capsules, capable of protecting different
bioactive agents like proteins and nuclei acids. Each and every polymer exhibits several chemical and
biological properties, making marine biomaterials and their derivatives excellent materials not only for the
construction of load devices but also for other pharmaceutical formulations as excipients or even active
compounds in some food supplements. Natural-origin biomaterials allow incorporating a wide variety of
proteins, drugs and nucleic acids, which for many new drugs would not be possible with many synthetic
materials, which may be even toxic for the body. The release of bioactive agents may occur through
various mechanisms, which may be controlled by using stimuli-responsive polymers to promote a fast
or a sustained release. Because these materials are often biocompatible and biodegradable, their use
may augment the efficiency of encapsulation and promote the protection of a bioactive agent.
Nowadays, it is already possible to find systems able to control the release of therapeutic
molecules for the treatment of genetic diseases. Despite the great knowledge and wide use of marine
polysaccharides in the pharmaceutical industry, some challenges remain unsolved, such as the efficient
targeted delivery, the perfect control over the release rate to fit within a therapeutic window, and the
adaptability to administration routes that are more patient compliant (e.g., oral instead of intravenous).
Therefore, further investigation will be required to improve the isolation and purification of marine
biopolymers, as well as the synthesis of their chemical modification and processing into the various
possible matrices shapes. It is expected that in the short-term such control will lead to more efficient
loading, higher degrees of control over the release and improved DDS designs, that could be used in
advanced therapies. This could be possible by looking into the interactions between polymer, drugs and
native biological tissues, as well the intelligent response of the polysaccharides and targeting capability.
Future strategies should also combine the possibility of controlled release from this type of devices
with diagnostic capability (theranostics approaches) where platforms involving nanotechnologies and
image should be taken into consideration.
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